Zelira Therapeutics Ltd. announced that its insomnia medication Zenivol™ has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market. Zenivol™ is the first and only clinically validated, pharmaceutical-grade, cannabis-based sleep medication. Zenivol™'s clinical research achieved the higher level of scientific review when it was peer reviewed in the Journal of Sleep.

It is currently available by prescription in Australia under the country's legal cannabis regulations.